Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 532 clinical trials
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

In this open-label, randomized, prospective clinical trial, newly-diagnosed AML patients will be randomized into 2 groups. In the experimental arm, patients receive DA induction regimen with intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose …

daunorubicin
adult acute myelogenous leukemia
cytarabine/daunorubicin
cytarabine
neoadjuvant therapy
  • 36 views
  • 23 Jan, 2021
  • 1 location
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

The main purpose of this study is : To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction To compare mitoxantrone (anthracenedione) & cytarabine with liposomal …

ara-c
busulfan
myeloablative conditioning
gilbert's syndrome
minimal residual disease
  • 0 views
  • 26 Jan, 2021
  • 59 locations
A Trial to Evaluate the Safety and Efficacy of oNKord in Subjects With Acute Myeloid Leukemia

WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord in 33 adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable

cell transplantation
hematologic disorder
gilbert's syndrome
consolidation chemotherapies
fludarabine
  • 0 views
  • 24 May, 2021
  • 8 locations
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

  • 0 views
  • 13 May, 2021
  • 1 location
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

ara-c
carbon monoxide
azacitidine
gilbert's syndrome
hemolysis
  • 2 views
  • 16 May, 2021
  • 59 locations
TL-895 and KRT-232 Study in Acute Myeloid Leukemia

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for …

tyrosine
TP53
  • 0 views
  • 22 May, 2021
  • 7 locations
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

refractory acute myeloid leukemia (aml)
  • 89 views
  • 20 Jun, 2021
  • 68 locations
A Phase 1 First in Human Study of ZN-d5 as a Single Agent

with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).

t-cell lymphoma
gilbert's syndrome
platelet count
serum bilirubin level
anthracyclines
  • 0 views
  • 19 Jun, 2021
  • 13 locations
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2 With an IDH1 or IDH2 Mutation Respectively Eligible for Intensive Chemotherapy

AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 …

hematologic disorder
gilbert's syndrome
neoadjuvant therapy
enasidenib
IDH2
  • 13 views
  • 23 Jan, 2021
  • 1 location
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted

hematologic disorder
tyrosine
serum bilirubin level
myelodysplastic syndromes
consolidation therapy
  • 10 views
  • 23 Jan, 2021
  • 1 location